New Biomarker Signals Poor Response in Prostate Cancer New Biomarker Signals Poor Response in Prostate Cancer

A new test identifies men with castration-resistant prostate cancer who have a poorer response to abiraterone and enzalutamide.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news